A peer-reviewed version of this preprint was published in PeerJ on 27 August 2015.

View the peer-reviewed version (peerj.com/articles/1156), which is the preferred citable publication unless you specifically need to cite this preprint.

Ciulla MM, Astuti M, Carugo S. 2015. The atherosclerosis of the sinus node artery is associated with an increased history of supra-ventricular arrhythmias: a retrospective study on 541 standard coronary angiograms. PeerJ 3:e1156 https://doi.org/10.7717/peerj.1156
The atherosclerosis of the sinus node artery is associated with an increased history of supra-ventricular arrhythmias: A retrospective study on 541 standard coronary angiograms

Michele M Ciulla, Matteo Astuti, Stefano Carugo

BACKGROUND: The ischemic damage of the sinus node (SN) is a well known cause of cardiac arrhythmias and can be a consequence of any flow abnormality in the sinus node artery (SNA). Accordingly we aimed this retrospective study to: 1. evaluate the suitability of the standard coronary angiography to study the SNA and 2. determine if the percentage of subjects with a positive retrospective history of supra-ventricular arrhythmias (SVA) differs in patients with normal and diseased SNA ascertained at the time of coronary angiography. METHODS and RESULTS: out of the 541 coronary angiograms reviewed the SNA was visible for its entire course in 486 cases (89.8%). It was found to arise from the right side of the coronary circulation in 266 cases (54.7%) slightly more often than from the left, 219 cases (45.1%). One patient had 2 distinct SNA arising from either side of the coronary circulation. For the second objective we studied the 333 patients with: a. coronary artery disease (CAD), b. properly evaluable SNA and c. complete clinical history available. In 51 (15.3%) a SNA disease was found, the 41.2% of them had a positive SVA history, mainly atrial fibrillation (AF), whereas only the 7.4% of patients with a positive history of SVA could be found in the non-SNA diseased. This difference was statistically significant (P< 0.001). CONCLUSIONS: 1- The evaluation of the SNA is feasible in clinical practice during a standard coronary angiography; 2- this may be relevant since angiographically detectable SNA disease was significantly associated with a positive history of SVA.
The atherosclerosis of the sinus node artery is associated with an increased history of supra-ventricular arrhythmias. A retrospective study on 541 standard coronary angiograms.

1,2 Michele M Ciulla, 2,3 Matteo Astuti, and 4 Stefano Carugo

1 Laboratory of Clinical Informatics and Cardiovascular Imaging; 2 Department of Clinical Sciences and Community Health, University of Milan, Milan, (Italy); 3 Cardiovascular Diseases Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan (Italy); 4 Department of Health Sciences, University of Milan, Milan (Italy).

Corresponding author:
Laboratory of Clinical Informatics and Cardiovascular Imaging
Via F. Sforza, 35 20122 Milan, Italy
Tel +39-0255033592, Fax +39-0250320480
E-mail: michele.ciulla@unimi.it

Key words: supraventricular arrhythmias, sinus node artery, atrial fibrillation, ischemia, atherosclerosis, coronary angiography.
ABSTRACT

BACKGROUND: the ischemic damage of the sinus node (SN) is a well known cause of cardiac arrhythmias and can be a consequence of any flow abnormality in the sinus node artery (SNA). Accordingly we aimed this retrospective study to: 1. evaluate the suitability of the standard coronary angiography to study the SNA and 2. determine if the percentage of subjects with a positive retrospective history of supra-ventricular arrhythmias (SVA) differs in patients with normal and diseased SNA ascertained at the time of coronary angiography.
METHODS and RESULTS: out of the 541 coronary angiograms reviewed the SNA was visible for its entire course in 486 cases (89.8%). It was found to arise from the right side of the coronary circulation in 266 cases (54.7%) slightly more often than from the left, 219 cases (45.1%). One patient had 2 distinct SNA arising from either side of the coronary circulation. For the second objective we studied the 333 patients with: a. coronary artery disease (CAD), b. properly evaluable SNA and c. complete clinical history available. In 51 (15.3%) a SNA disease was found, the 41.2% of them had a positive SVA history, mainly atrial fibrillation (AF), whereas only the 7.4% of patients with a positive history of SVA could be found in the non-SNA diseased. This difference was statistically significant (P< 0.001).

CONCLUSIONS: 1- The evaluation of the SNA is feasible in clinical practice during a standard coronary angiography; 2- this may be relevant since angiographically detectable SNA disease was significantly associated with a positive history of SVA.
1. INTRODUCTION

The supraventricular arrhythmias, especially AF, have a high prevalence in the general population and, especially in patients with CAD, are a major social and economic burden in terms of mortality and morbidity. [1]. Although many features of their etiology and electrophysiology have already been cleared, some aspects of the SVA pathogenesis still are not. With the present study we aimed to explore the possible relationship between a positive retrospective clinical history of SVA and the atherosclerotic disease of the SNA ascertained at the time of coronary angiography. The hypothesis that ischemic damage to the vessels that supply the atrial excito-conducting tissue may impair its function leading to abnormal heart rhythms has sound pathophysiological basis. Indeed the SNA plays an essential role in ensuring the normal operation of SN as a servomechanism [2], in maintaining its structural integrity and, in particular, of the collagen matrix that seems to be crucial for the electrical stability of the heart. Furthermore, since the SNA supplies blood to a much larger area than the SN alone, the ischemia secondary to a stenosis of this vessel could give rise to a widespread structural and electrical remodeling, which, as it is known, represents the underlying substrate to most of SVA.

The association between the obstruction of the atrial coronary branches with the occurrence of such arrhythmias during the first phase of a myocardial infarction was already shown several years ago with classical anatomical and imaging studies [3,4,5,6], unfortunately there are no studies that take into account the effects of the SNA atherosclerosis as a process on the heart rhythm. Therefore we designed this retrospective study with the purpose to: 1- determine if the standard coronary angiography is a suitable method to assess the SNA by calculating the percentage of angiography where it was possible to detect the SNA; 2- provide further anatomical data about the prevalence of left and right sided SNA in Italy and 3- evaluate if, in
patients with an angiographically detectable and clearly assessable disease of the SNA at the
time of coronary angiography, the prevalence of a retrospective clinical history of SVA
attributable to a SN hypoperfusion, significantly differs from that in patients with a normal SNA.

2. MATERIALS AND METHODS

2.1. STUDY POPULATION

In the present study we retrospectively analyzed the coronary angiograms performed in the
catheterization laboratory of our hospital from May 2013 to May 2014. In those cases where a
patient repeated the coronary angiogram procedure only the older images were taken into
account. The coronary angiograms of subjects who had previously undergone by-pass surgery
were not reviewed. All these exams were suitable for the first and second objective of the study.

To achieve the third objective focused on the prevalence of the disease the SVA in subjects with
and without a previous clinical history of SVA, some exclusion criteria were set up: a- the
subjects in which the SNA could not be entirely and properly evaluated were excluded; this
group includes patients with acute coronary syndrome (ACS) where the SNA branched
downstream the culprit lesion; b- the subjects whose clinical report was not available or
incomplete were also excluded as those in which intact coronary arteries were detected.

For each patient the required variables up to the time of the coronary catheterization were
extracted from the clinical report of the hospitalization when the coronary angiography was
performed; in particular we collected carefully all the information related to a positive history of
SVA and to the presence of known risk factors for CAD and SVA, also the main
echocardiographic data and any active anti-arrhythmic therapy were. To ensure that the
experimenters was effectively blinded to the identity of the patients, we have worked on a fully
de-identified database containing only the variables in study with a random assignment of an
identification code that does not allow investigators to retrieve the identity of the subjects; thus also the need for approval by the IRB was waived.

In the present study we have included in the SVA all the rhythm disturbances originating from the tissues above the level of the ventricles; furthermore, the atrio-ventricular blocks or conduction delays have not been taken into account as they are a consequence of a lesion of the atrio-ventricular node which does not depend on the SNA for its blood supply. Finally were excluded the cases where the SVA has arisen for the first time in the early phase of an ACS since the pathogenesis of these acute events is not the object of the present study.

2.2. ANGIOGRAPHIC ANALYSIS

All the coronary angiographies were performed for diagnostic and therapeutic purpose, including both urgent procedures in patients with ACS and elective procedures in patients with stable coronary artery disease or candidates to heart surgery. The selective right and left coronary angiography was performed using a digital cineangiography imaging system (InfinixCS-i, Toshiba, Japan). All images were stored as DICOM data and were analyzed off-line. Since the angiographies were standard procedures, no specific projections were available to study the SNA, thus, all the coronary angiograms were carefully analyzed to assess the SNA, including its presence and origin.

For the third objective of the study, among the examinations where the SNA was fully assessable, those with intact coronary arteries were excluded, on the contrary, angiograms showing a subcritical diffuse coronary artery disease or an already-in-place stent were included. Thus the images were analyzed for the presence of a lesion involving the SNA and the patients
were then grouped accordingly. The SNA disease was assessed by applying the standard criteria commonly used for the main subepicardial coronary arteries; not only critical stenosis where taken into account, but also a diffuse irregularity of the arterial wall was considered expression of a pathological vessel. When a chronic lesion of the left circumflex coronary artery (LCX) or the right coronary artery (RCA) was found upstream the SNA origin, the patient was assigned to the group with SNA disease.

2.3. STATISTICAL ANALYSIS

Continuous variables were expressed as median and interquartile range. Categorical variables were expressed as absolute numbers and percentages. The differences in continuous variables were assessed using the Mann–Whitney U test when not normally distributed and the Student t test when normally distributed. X² test was used to test for differences in categorical variables, unless more than 20% of the cells of the 2x2 table had an expected value < 5, in these cases the exact Fisher test was performed. Multivariate analysis was performed to evaluate the relationship between demographic and clinical data. Odds ratios and 95% CI were calculated.

All tests were 2-sided and a probability value < 0.05 was considered statistically significant.

Statistical analyses were performed using SPSS software (version 20, IBM, US).

3. RESULTS

The size of the sample studies was adequate and the power was calculated (1 - β = 0.9976), with a type I error rate of 5%. Out of the 541 coronary angiograms reviewed, the SNA was detectable and was visible for its entire course in 486 cases (89.8 %); it was found to arise from the right side of the coronary circulation in 266 cases (54.7%) slightly more often than from the left, 219 cases (45.1%). One patient had 2 distinct SA nodal arteries arising from either side of the
coronary circulation (Table 1). Following the exclusion criteria, 67 subjects were excluded since their medical record was not available, 107 for the lack of an angiographically detectable CAD in the major epicardial arteries and 34 because the SNA could not be properly evaluated.

The remaining 333 were divided into four groups according to the presence/absence of SNA disease and previous clinical history of SVA. The flow chart that shows the selection of patients and the assignment to the study groups is reported in Figure 1. The clinical profile of each group is shown in Table 2; representative coronary angiograms are shown in Figure 2. All patient groups were homogeneous in median age and gender. The indication to the coronary catheterization was an ACS in 217 cases (65.2%), 94 (43.3%) of which were ST-segment elevation myocardial infarction. In the remaining cases the coronary angiography was an elective procedure. No significant differences were found in the distribution of the indication to the coronary catheterization among the groups. Out of the total 333 cases, in 51 (15.3%) a SNA disease was found, in 26 cases the lesion consisted of a diffuse irregularity of the SNA wall, in 19 cases it was a focal stenosis of the SNA and in the remaining 6 cases the lesion was located in the LCX or RCA upstream the SNA origin (see Figure 2). The prevalence of a previous clinical history of SVA was significantly higher in the SNA diseased group than in the non-SNA diseased (41.2 % vs 7.4 % P < 0.001) (Table 2). When taking into consideration the classification of SVA reported and their distribution according to the presence/absence of SNA disease, no significant differences where found (Table 3). The prevalence of known risk factors for CAD and SVA and of the cardiovascular therapies was homogeneous among all the groups with the following exceptions: the subjects with SNA disease had a significantly higher prevalence of prior acute myocardial infarction (AMI) (43.1 % vs 23.8 %; P=0.004), a significantly lower left ventricle ejection fraction (51.0 % vs 36.2 %; P=0.045) and a
significantly higher use of beta-blockers (47.1 % vs 31.2 %; P=0.027) and thienopyridines (23.5 % vs 12.4 %; P=0.036) than non-SNA diseased. As expected, in subjects with a clinical history of SVA, irrespective of the presence of SNA disease, a higher prevalence of risk factors for arrhythmia, including a higher prevalence of reduced left ventricle ejection fraction and atrial dilatation, was found alongside with a significantly higher consumption of antiarrhythmic drugs (Table 2).

4. DISCUSSION

With the present study we demonstrated that the evaluation of the vessel deputed to vascularization of the SN is feasible without particular effort during a standard coronary angiography. We found that the SNA could be entirely visualized in the 89.8 % of the examined cases. Previous studies aimed to visualize the SNA by using the same technique have reported an higher percentage of visualization [8]. This difference can be explained by the fact that those exams were specifically carried out to identify the SNA and this was not the case of the present study which is based on coronary angiograms performed with projections aimed to visualize and, eventually, treat lesions on the major epicardial coronary arteries. At this regard, we think that the real life data provided by this study may have a more immediate impact on the clinical practice suggesting to check when feasible the patency of the SNA during a standard coronary angiography especially in the presence of a history of SVA. Furthermore we provide some additional anatomic information regarding the left rather than right-sided origin of the SNA with the latter found to be slightly more frequent (57.7 % vs 45.1 %), confirming the previous findings of older studies in European, North American and Brazilian subjects [9,10,11]. According to our experience the angiographic projection to visualize the SNA vary depending on the inconstant position and course of this vessel, though, in our experience, a right-sided SNA
can be better visualized with a Right Anterior Oblique (RAO) straight (-30°; 0°) or a Left Anterior Oblique (LAO) cranial (+45°; +20°) view, whereas a LAO caudal “spider” view (+45°; -30°) or a RAO caudal view (-20°; -20°) are the most suitable to show a left-sided SNA branching from the proximal LCX.

Beside this, we wanted to explore the relationship between heart rhythm and atherosclerosis of the SNA. It has already been demonstrated that SVA, and in particular AF, are associated with an increased prevalence of CAD [12] and even subclinical CAD [13], in the present study we wanted to better delineate the specific role of the SNA disease at the time of coronary angiography in this context. Therefore, the most relevant finding of this study was that, among 333 patients with angiographically detectable CAD, the prevalence of a retrospective clinical history of SVA, mainly AF, was significantly higher in the subjects with a diseased SNA (Figure 4). The fact that also the prevalence of prior AMI and of reduced left ventricle ejection fraction is significantly more elevated in the same group, and consequently an increased beta-blockers and thienopyridine antiplatelets usage, may be a consequence of a more severe CAD with an increased probability of the involvement of minor coronary branches such as the SNA. Furthermore, the difference in myocardial contractile function cannot be considered a confounding factor, in fact, though it is a well known risk factor for SVA, this pro-arrhythmic action involves an increase in telediastolic ventricular pressure and a consequent increased atrial pressure and volume overload (6) that leads to atrial dilatation and stretch, but in the present study the prevalence of atrial dilatation did not significantly differ between subjects with and without SNA disease.

Different studies were carried on to investigate the possible relationship between SVA, mainly AF, and atherosclerosis in general and coronary arteries atherosclerosis in particular. A cohort
study demonstrated that the risk of AF was associated with carotid intima-media thickness (IMT) and severity of carotid plaques [14]. A further study confirmed the association between lone AF with increased carotid IMT and arterial stiffness. In this case, arterial stiffness was found to be higher in persistent than paroxysmal lone AF patients suggesting that a gradation of subclinical vascular disease can be associated with a parallel gradation of the severity of AF [15].

A case-control study found a higher prevalence of obstructive CAD, assessed by Multislice Computed Tomography Coronary Angiography among patients with paroxysmal or persistent AF [12]. On the other hand the specific role of SNA disease in the genesis of SVA was also explored, but in limited situations. Previous angiographic [3,4,5] and anatomical [6] studies succeeded in demonstrating the relation between an acute occlusion of the atrial coronary branches, including the SNA, and the onset of SVA in the early stages of AMI. Finally angiographically detectable SNA disease was significantly associated with AF post-coronary artery bypass graft surgery [8,16].

The present study is a step in the understanding of the complex role of atherosclerotic disease and CAD in the genesis of supra-ventricular rhythm disturbances for different reasons. First we demonstrated a statistically significant association between SNA disease at the time of coronary angiography and the prevalence of a retrospective clinical history of SVA attributable to a SN hypoperfusion in a context different from the acute phase of an ACS and in a population of patients wider than the candidates for by-bass surgery. Second, the results of this study suggest an interesting physiopathological mechanism of chronic SVA even if the design of this study does not allow us to draw any conclusion regarding a causal relationship between the disease of the SNA and SVA. Nevertheless we have already explained the different pathophysiological ways through which a lesion that determines a flow abnormality in the SNA may affect the heart.
rhythm, that said, we do not think that SNA disease is necessary, though may be sufficient, to provoke a SVA, but it should be regarded as one of the SVA risk factors along with arterial hypertension, heart failure, valvular disease and so on.

This study has some limitations that should be acknowledged. First, it is a case-control study, the limitations of which are well known. A larger study, with follow-up data, may provide more conclusive information. Second, this study is limited by attempting to correlate angiographic anatomy rather than ischemia per se, but there is currently no reliable means of assessing atrial ischemia. Third, angiographic images are the current gold standard to show alterations of the arterial lumen, but they cannot give sure information regarding the their atherosclerotic nature. An IVUS study should be more conclusive in this sense, but it is currently unavailable for such a narrow vessel as the SNA. These limitations do not diminish the value of the result of this study, which provides new data supporting the association between the disease of a specific branch of the coronary circulation and a positive history of SVA.

REFERENCES

[1] Sanoski CA. Clinical, economic, and quality of life impact of atrial fibrillation. J Manag Care Pharm. 2009; 15 (6 Suppl B):S4-9.

[2] James TN. The sinus node as a servomechanism. Circ Res 1973; 32:307-313.

[3] Kyriakidis M, Barbetseas J, Antonopoulos A, Skouros C, Tentolouris C, Toutouzas P. Early atrial arrhythmias in acute myocardial infarction. Role of the sinus node artery. Chest. 1992;101(4):944-7.
[4] Tjandrawidjaja MC, Fu Y, Kim DH, Burton JR, Lindholm L, Armstrong PW; CAPTORS II Investigators. Compromised atrial coronary anatomy is associated with atrial arrhythmias and atrioventricular block complicating acute myocardial infarction. J Electrocardiol. 2005;38(3):271-8.

[5] Hod H, Lew AS, Kelta M, Cercek B, Geft IL, Shah PK, Ganz W. Early atrial fibrillation during evolving myocardial infarction: a consequence of impaired left atrial perfusion. Circulation. 1987;75(1):146-50.

[6] James TN. Myocardial infarction and atrial arrhythmias. Circulation. 1961;24:761-76.

[7] European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429.

[8] Al-Shanafey S, Dodds L, Langille D, Ali I, Henteleff H, Dobson R. Nodal vessels disease as a risk factor for atrial fibrillation after coronary artery bypass graft surgery. Eur J Cardiothorac Surg. 2001;19(6):821-6.

[9] Cezlan T, Senturk S, Karcaaltincaba M, Bilici A. Multidetector CT imaging of arterial supply to sinuatrial and atrioventricular nodes. Surg Radiol Anat. 2012 May;34(4):357-65.

[10] Saremi F, Abolhoda A, Ashikyan O, Milliken JC, Narula J, Gurudevan SV, Kaushal K, Raney A. Arterial supply to sinuatrial and atrioventricular nodes: imaging with multidetector CT. Radiology. 2008 Jan;246(1):99-107.
[11] Ortale JR, Paganoti Cde F, Marchiori GF. Anatomical variations in the human sinuatrial nodal artery. Clinics (Sao Paulo). 2006 Dec;61(6):551-8.

[12] Nucifora G, Schuijf JD, Tops LF, van Werkhoven JM, Kajander S, Jukema JW, Schreur JH, Heijenbrok MW, Trines SA, Gaemperli O, Turta O, Kaufmann PA, Knuuti J, Schalij MJ, Bax JJ. Prevalence of coronary artery disease assessed by multislice computed tomography coronary angiography in patients with paroxysmal or persistent atrial fibrillation. Circ Cardiovasc Imaging. 2009;2(2):100-6.

[13] The Task Force on the management of stable coronary artery disease of the European Society of Cardiology (ESC). 2013 ESC guidelines on the management of stable coronary artery disease-addenda. European Heart Journal (2013) 34, 2949–3003

[14] Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Rooij FJ, Lip GY, Witteman JC. Subclinical atherosclerosis and risk of atrial fibrillation: the Rotterdam study. Arch Intern Med 2007 26;167(4):382-7.

[15] Chen LY, Foo DC, Wong RC, Seow SC, Gong L, Benditt DG, Ling LH. Increased carotid intima-media thickness and arterial stiffness are associated with lone atrial fibrillation. Int J Cardiol. 2013 Oct 3;168(3):3132-4.

[16] Kolvekar S, D'Souza A, Akhtar P, Reek C, Garratt C, Spyt T. Role of atrial ischaemia in development of atrial fibrillation following coronary artery bypass surgery. Eur J Cardiothorac Surg. 1997;11(1):70-5.
Figure legends

Figure 1

Flow chart showing patient selection according to the exclusion criteria. *: patients without medical record were excluded (n=67); **: only the older angiography was considered for those patients who repeated the exam; ***: this group comprehends the images obtained from the primary coronary catheterizations of patients affected by ACS where the SNA branched downstream the culprit lesion.

Figure 2

Representative angiographic images of the SNA (arrows) demonstrating the general feasibility of its visualization. Panel A: a normal SNA; Panel B: SNA with a focal stenosis (arrowhead); Panel C: diffuse atherosclerotic disease involving also the SNA; Panel D: stenosis of the main left coronary artery upstream the SNA (arrowhead).
Table 1 (on next page)

SNA anatomy.

Senza nome1 Summary of the anatomical characteristics of the SNA visualized in this study.
|                           | n°  | %  |
|---------------------------|-----|----|
| Total number of coronary  | 541 |    |
| angiograms reviewed       |     |    |
| entirely visible SNA      | 486 | 89,8 |
| left-sided SNA            | 219 | 45,1 |
| right-sided SNA           | 266 | 54,7 |
| bilateral SNA             | 1   | 0,2 |
Table 2 (on next page)

Characteristics of the studied patients.

Tables Patients groups and characteristics. SVA +: subjects with a positive history of SVA. SVA -: subjects without a positive history of SVA. P < 0.05 is considered statistically significant. P1: comparison between subjects affected by SNA disease with and without SVA. P2: comparison between subjects not affected by SNA disease with and without SVA. P3: comparison between subjects with and without SNA disease. P3c: correction for multiple testing.
## Characteristics

| Characteristics                     | Total | SNA disease | No SNA disease | P values |
|-------------------------------------|-------|-------------|----------------|----------|
|                                     |       | Total | SVA + | SVA - | Total | SVA + | SVA - | P1 | P2 | P3 | P3c |
| Patients groups n°                  | 333   | 51    | 21    | 30    | 282   | 21    | 261   |     |    |    |     |
| Patients groups %                   | 100   | 15.3  | 41.2  | 58.8  | 84.7  | 7.4   | 92.6  |     |    |    |     |
| Age (yr) Median                     | 68    | 73    | 77    | 69.5  | 67    | 74    | 66    | 0.052 | 0.059 | 0.058 | 0.178 |
| IR 60-78                           | 61-80 | 70-82 | 57-78 | 59-76 | 70-78 | 58-76 |       |     |    |    |     |
| Female sex n°                       | 88    | 11    | 5     | 6     | 77    | 6     | 71    | 0.744 | 0.892 | 0.393 | 0.251 |
| Female sex %                        | 26.4  | 21.6  | 23.8  | 20.0  | 27.3  | 28.6  | 27.2  |       |     |    |     |
| ACS (STEMI) n°                      | 217   | 32    | 13    | 19    | 185   | 10    | 175   | 0.917 | 0.071 | 0.693 | 0.438 |
| ACS (STEMI) %                       | 65.2  | 61.9  | 63.3  | 65.6  | 47.6  | 67.0  |       |     |    |    |     |
| Hypertension requiring treatment n° | 237   | 42    | 20    | 22    | 195   | 15    | 180   | 0.640 | 0.814 | 0.055 | 0.732 |
| Hypertension requiring treatment %  | 71.2  | 82.4  | 95.2  | 73.3  | 69.1  | 71.4  | 69.0  |       |     |    |     |
| Prior AMI n°                        | 89    | 22    | 10    | 12    | 67    | 3     | 64    | 0.589 | 0.425 | 0.004 | 0.025 |
| Prior AMI %                         | 26.7  | 43.1  | 47.6  | 40.0  | 23.8  | 14.3  | 24.5  |       |     |    |     |
| DM n°                               | 75    | 11    | 3     | 8     | 64    | 2     | 62    | 0.490 | 0.178 | 0.859 | 0.627 |
| DM %                                | 22.5  | 21.6  | 14.3  | 26.7  | 22.7  | 9.5   | 23.8  |       |     |    |     |
| PAD n°                              | 89    | 18    | 9     | 9     | 71    | 7     | 64    | 0.344 | 0.371 | 0.133 | 0.604 |
| PAD %                               | 26.7  | 35.3  | 42.9  | 30.0  | 25.2  | 33.3  | 24.5  |       |     |    |     |
| **Smoke**                           |       |       |       |       |       |       |       | 0.189 | 0.221 | 0.693 | 0.097 |
| Current n°                          | 89    | 14    | 3     | 11    | 75    | 3     | 72    |       |     |    |     |
| Current %                           | 26.7  | 27.5  | 14.3  | 36.7  | 26.6  | 14.3  | 27.6  |       |     |    |     |
| Former n°                           | 84    | 15    | 8     | 7     | 69    | 8     | 61    |       |     |    |     |
| Former %                            | 25.2  | 29.4  | 38.1  | 23.3  | 24.5  | 38.1  | 23.4  |       |     |    |     |
| Never n°                            | 160   | 22    | 10    | 12    | 138   | 10    | 128   |       |     |    |     |
| Never %                             | 48.1  | 43.1  | 47.6  | 40.0  | 48.9  | 47.6  | 49.0  |       |     |    |     |
| Left ventricle ejection fraction <55%| 128   | 26    | 12    | 14    | 102   | 13    | 89    | 0.461 | 0.011 | 0.045 | 0.756 |
| Left ventricle ejection fraction <55%| %     | 38.4  | 51.0  | 57.1  | 46.7  | 36.2  | 61.9  | 34.1  |       |     |    |     |
| **Atrial dilatation**               |       |       |       |       |       |       |       | **0.014** | **0.017** | 0.431 | 0.319 |
| na n°                               | 145   | 18    | 7     | 11    | 127   | 7     | 120   |       |     |    |     |
| na %                                | 43.4  | 35.3  | 33.3  | 36.7  | 45.0  | 33.3  | 46.0  |       |     |    |     |
| no n°                               | 110   | 19    | 4     | 15    | 91    | 4     | 87    |       |     |    |     |
| no %                                | 33.0  | 37.3  | 19.1  | 50.0  | 32.3  | 19.0  | 33.3  |       |     |    |     |
| yes (mild) n°                        | 78 (45)| 14 (11)| 10 (7)| 4 (4)| 64 (34)| 10 (2)| 54 (32)|       |     |    |     |
| yes (mild) %                         | 23.4 (57.7)| 27.4 (78.6)| 47.6 (70)| 13.3 (100)| 22.7 (53.1)| 47.7 (20)| 20.7 (59.3)|       |     |    |     |
| Characteristics                        | Total | SNA disease | No SNA disease | P values |
|----------------------------------------|-------|-------------|----------------|----------|
|                                        |       | SVA + | SVA - | Total | SVA + | SVA - | Total | SVA + | SVA - | P1 | P2 | P3 |
| Cholesterol level: total (mg/dl)       |       |       |       |       |       |       |       |       |       |     |    |    |
| MEDIAN                                | 172   | 166   | 172   | 153   | 172   | 149   | 173   | 0.939 | 0.05  | 0.302 |
| IR                                    | 143.5 -200.5 | 143-190 | 155-191 | 136-186 | 144-204.5 | 136-180 | 145-208 | 0.153 | 0.986 | 0.337 |
| Cholesterol level: HDL (mg/dl)        |       |       |       |       |       |       |       |       |       |     |    |    |
| MEDIAN                                | 35.5-52 | 35.5-49.5 | 38.5-50 | 32.48 | 36-52 | 37-53 | 35-52 | 0.916 | 0.038 | 0.379 |
| IR                                    | 82-153.5 | 83-149 | 95-145 | 79-153 | 82-155 | 63-131 | 88-159 | 0.506 | 0.267 | 0.230 |
| TGL (mg/dl)                           |       |       |       |       |       |       |       |       |       |     |    |    |
| MEDIAN                                | 115   | 105   | 110   | 104   | 117   | 95    | 119   | 0.961 | 0.004 | 0.108 |
| IR                                    | 82-153.5 | 83-149 | 95-145 | 79-153 | 82-155 | 63-131 | 88-159 | 0.506 | 0.267 | 0.230 |
| Hyperthyroidism                       |       |       |       |       |       |       |       |       |       |     |    |    |
| N*                                    | 6     | 2     | 0     | 2     | 4     | 1     | 3     | 0.92 | 0.006 | 0.029 |
| %                                     | 1.8   | 3.9   | 0.0   | 6.7   | 1.4   | 4.8   | 1.1   | 0.092 | 0.004 | 0.108 |
| Renal function, creatinine clearance (ml/min) |       |       |       |       |       |       |       |       |       |     |    |    |
| CKD stage 0-1, ≥ 90                   |       |       |       |       |       |       |       |       |       |     |    |    |
| N*                                    | 78    | 9     | 1     | 8     | 69    | 2     | 67    | 0.092 | 0.004 | 0.108 |
| %                                     | 23.4  | 17.6  | 4.8   | 26.7  | 24.5  | 9.5   | 25.7  | 0.092 | 0.004 | 0.108 |
| CKD stage 2, ≥ 60 to 89               |       |       |       |       |       |       |       |       |       |     |    |    |
| N*                                    | 163   | 24    | 9     | 15    | 139   | 12    | 127   | 0.092 | 0.004 | 0.108 |
| %                                     | 48.9  | 17.6  | 4.8   | 26.7  | 24.5  | 9.5   | 25.7  | 0.092 | 0.004 | 0.108 |
| CKD stage 3, ≥ 30 to 59               |       |       |       |       |       |       |       |       |       |     |    |    |
| N*                                    | 79    | 13    | 8     | 5     | 66    | 6     | 60    | 0.092 | 0.004 | 0.108 |
| %                                     | 23.7  | 25.5  | 38.1  | 16.7  | 23.4  | 28.6  | 23.0  | 0.092 | 0.004 | 0.108 |
| CKD stage 4, ≥15 to 29                |       |       |       |       |       |       |       |       |       |     |    |    |
| N*                                    | 12    | 5     | 3     | 2     | 7     | 0     | 7     | 0.092 | 0.004 | 0.108 |
| %                                     | 3.6   | 9.8   | 14.3  | 6.6   | 2.5   | 0.0   | 2.7   | 0.092 | 0.004 | 0.108 |
| CKD stage 5, <15                      |       |       |       |       |       |       |       |       |       |     |    |    |
| N*                                    | 1     | 0     | 0     | 0     | 1     | 1     | 0     | 0.092 | 0.004 | 0.108 |
| %                                     | 0.3   | 0.0   | 0.0   | 0.0   | 0.3   | 4.8   | 0.0   | 0.092 | 0.004 | 0.108 |
| ACE inhibitor/ARB                     |       |       |       |       |       |       |       |       |       |     |    |    |
| N*                                    | 163   | 30    | 10    | 20    | 133   | 13    | 120   | 0.174 | 0.160 | 0.125 |
| %                                     | 48.9  | 58.8  | 47.6  | 66.7  | 47.2  | 61.9  | 46.0  | 0.174 | 0.160 | 0.125 |
| Amiodarone                            |       |       |       |       |       |       |       |       |       |     |    |    |
| N*                                    | 7     | 3     | 3     | 0     | 4     | 2     | 2     | 0.064 | 0.029 | 0.076 |
| %                                     | 2.1   | 5.9   | 14.3  | 0.0   | 1.4   | 9.5   | 0.8   | 0.064 | 0.029 | 0.076 |
| Beta-blocker                          |       |       |       |       |       |       |       |       |       |     |    |    |
| N*                                    | 112   | 24    | 11    | 13    | 88    | 9     | 79    | 0.524 | 0.231 | 0.027 |
| %                                     | 33.6  | 47.1  | 52.4  | 43.3  | 31.2  | 42.9  | 30.3  | 0.524 | 0.231 | 0.027 |
| Digoxin                               |       |       |       |       |       |       |       |       |       |     |    |    |
| N*                                    | 3     | 1     | 1     | 0     | 2     | 2     | 0     | 0.412 | 0.005 | 0.394 |
| %                                     | 0.9   | 2.0   | 4.8   | 0.0   | 0.7   | 9.5   | 0.0   | 0.412 | 0.005 | 0.394 |
| Calcium blocker                       |       |       |       |       |       |       |       |       |       |     |    |    |
| N*                                    | 59    | 10    | 3     | 7     | 49    | 7     | 42    | 0.495 | 0.067 | 0.701 |
| %                                     | 17.7  | 19.6  | 14.3  | 23.3  | 17.4  | 33.3  | 16.1  | 0.495 | 0.067 | 0.701 |
| ASA                                   |       |       |       |       |       |       |       |       |       |     |    |    |
| N*                                    | 156   | 26    | 10    | 16    | 130   | 9     | 121   | 0.688 | 0.757 | 0.520 |
| %                                     | 46.8  | 51.0  | 47.6  | 53.3  | 46.1  | 42.9  | 46.4  | 0.688 | 0.757 | 0.520 |
| Thienopyridine                        |       |       |       |       |       |       |       |       |       |     |    |    |
| N*                                    | 47    | 12    | 4     | 8     | 35    | 1     | 34    | 0.739 | 0.489 | 0.036 |
| %                                     | 14.1  | 23.5  | 19.0  | 26.7  | 12.4  | 4.8   | 13.0  | 0.739 | 0.489 | 0.036 |
| IC antiarrhythmic drugs | n° | 7 | 3 | 3 | 0 | 4 | 4 | 0 | 0.064 | < **0.001** | 0.076 |
|-------------------------|----|---|---|---|---|---|---|---|-------|---------|-------|
| %                       |    | 2.1 | 5.9 | 14.3 | 0.0 | 1.4 | 19.0 | 0.0 |       |         |       |
| Statin                  | n° | 110 | 19 | 8 | 11 | 91 | 7 | 84 | 0.917 | 0.914 | 0.486 |
| %                       |    | 33.0 | 37.3 | 38.1 | 36.7 | 32.3 | 33.3 | 32.2 |       |         |       |
| Sotalol                 | n° | 2 | 1 | 1 | 0 | 1 | 0 | 1 | 0.421 | 1 | 0.283 |
| %                       |    | 0.6 | 2.0 | 4.8 | 0.0 | 0.4 | 0.0 | 0.4 |       |         |       |
Table 3 (on next page)

Classification of SVA.

Senza nome1 Distribution of the different kinds of SVA observed according to the presence or not of SNA disease.
### Supraventricular arrhythmias

|                        | All patients | SNA disease | No SNA disease |
|------------------------|--------------|-------------|----------------|
| **Total**              | 42 (100)     | 21 (50)     | 21 (50)        |
| **AF**                 | 35 (83.3)    | 17 (81)     | 18 (85.7)      |
| Paroxysmal AF          | 9 (21.4)     | 5 (23.8)    | 4 (19)         |
| Persistent AF          | 12 (28.6)    | 7 (33.3)    | 5 (23.8)       |
| Permanent AF           | 14 (33.8)    | 5 (23.8)    | 9 (42.9)       |
| Sick sinus syndrome    | 3 (7.1)      | 3 (14.3)    | 0 (0)          |
| SV PACs requiring antiarrhythmic therapy | 2 (4.8) | 0 (0) | 2 (9.5) |
| Paroxysmal supraventricular tachycardia | 2 (4.8) | 1 (4.8) | 1 (4.8) |
Flow chart showing patient selection according to the exclusion criteria.

Flow chart showing patient selection according to the exclusion criteria. *: patients without medical record were excluded (n=67); **: only the older angiography was considered for those patients who repeated the exam; ***: this group comprehends the images obtained from the primary coronary catheterizations of patients affected by ACS where the SNA branched downstream the culprit lesion.
Representative angiographic images of the SNA (arrows) demonstrating the general feasibility of its visualization.

Representative angiographic images of the SNA (arrows) demonstrating the general feasibility of its visualization. Panel A: a normal SNA; Panel B: SNA with a focal stenosis (arrowhead); Panel C: diffuse atherosclerotic disease involving also the SNA; Panel D: stenosis of the main left coronary artery upstream the SNA (arrowhead).